Difference between revisions of "Mitochondria-Targeted Drug Development 2022 Boston US"
Beno Marija (talk | contribs) |
Beno Marija (talk | contribs) |
||
| Line 2: | Line 2: | ||
{{Publication | {{Publication | ||
|title=[[File:21640 - Mitochondria Targeted Therapeutics logo NEW.jpg|right|200px|Mitochondria Targeted Therapeutics]]'''Boston, MA US''', 2022 Feb 22-24. 2nd Annual Mitochondria-Targeted Drug Development - Overcome the Challenge of Treating Unmet Medical Needs Caused by Mitochondrial Dysfunction | |title=[[File:21640 - Mitochondria Targeted Therapeutics logo NEW.jpg|right|200px|Mitochondria Targeted Therapeutics]]'''Boston, MA US''', 2022 Feb 22-24. 2nd Annual Mitochondria-Targeted Drug Development - Overcome the Challenge of Treating Unmet Medical Needs Caused by Mitochondrial Dysfunction | ||
|info=https://mitochondria-targets.com/ | |info=[https://mitochondria-targets.com/program/full-event-guide/?utm_source=external&utm_medium=event-listing&utm_campaign=event-listing&utm_content=media-partner/other-mitoglobal-/unpaid/ev-26959 Conference website] | ||
|authors=hansonwade | |authors=hansonwade | ||
|year=2022-02-22 | |year=2022-02-22 | ||
| Line 13: | Line 13: | ||
== General information == | == General information == | ||
:::: | :::: We are happy to announce that the [https://mitochondria-targets.com/program/full-event-guide/?utm_source=external&utm_medium=event-listing&utm_campaign=event-listing&utm_content=media-partner/other-mitoglobal-/unpaid/ev-26959 Mitochondria-Targeted Drug Development Summit], focused on the pursuit for novel effective therapies for mitochondrial disorders/dysfunction, will be delivered in-person, for its 2nd edition. | ||
Incorporating insights from leading academics and pioneering biotech, this forum will specifically focus on targeting mitochondrial dysfunction to develop therapies for chronic diseases caused by mitochondrial DNA mutation/nuclear DNA mutations, muscle dystrophy diseases/muscle loss, metabolic disorders, neurodegenerative disease, and conditions linked to oxidative damage. | |||
From basic research to the clinic, this year’s meeting will examine novel preclinical animal modelling solutions specifically targeting mitochondria, deliver an update on the current leading clinical trials showcasing mitochondrial transfer, mutations, metabolism, quality control, biogenesis, and peroxidation/ oxidation, along with dedicated sessions on the significance on informatics and data sharing for precision medicine. | |||
Join 80+ leading experts as they navigate common challenges and opportunities for treating unmet medical needs caused by mitochondrial dysfunction. '''Mitobridge/Astellas, Minovia Therapeutics, Abliva, GenSight Biologics, Stealth Biotherapeutics''' and many more will unite drive to better understand how to create effective and scalable mitochondrial therapies. | |||
Revision as of 16:01, 23 November 2021
|
|
|
|
|
MitoGlobal first |
Mitochondria-Targeted Drug Development 2022 Boston US
 |
hansonwade (2022-02-22) MitoGlobal
Abstract: 2nd Annual Mitochondria-Targeted Drug Development, Boston MA, US, 2022.
General information
- We are happy to announce that the Mitochondria-Targeted Drug Development Summit, focused on the pursuit for novel effective therapies for mitochondrial disorders/dysfunction, will be delivered in-person, for its 2nd edition.
Incorporating insights from leading academics and pioneering biotech, this forum will specifically focus on targeting mitochondrial dysfunction to develop therapies for chronic diseases caused by mitochondrial DNA mutation/nuclear DNA mutations, muscle dystrophy diseases/muscle loss, metabolic disorders, neurodegenerative disease, and conditions linked to oxidative damage.
From basic research to the clinic, this year’s meeting will examine novel preclinical animal modelling solutions specifically targeting mitochondria, deliver an update on the current leading clinical trials showcasing mitochondrial transfer, mutations, metabolism, quality control, biogenesis, and peroxidation/ oxidation, along with dedicated sessions on the significance on informatics and data sharing for precision medicine.
Join 80+ leading experts as they navigate common challenges and opportunities for treating unmet medical needs caused by mitochondrial dysfunction. Mitobridge/Astellas, Minovia Therapeutics, Abliva, GenSight Biologics, Stealth Biotherapeutics and many more will unite drive to better understand how to create effective and scalable mitochondrial therapies.
- Download the brochure here
Program
- The program is available here
Registration
- Register here
- Early bird & Team Discounts Available until Dezember, 17
Organizer
- Hanson Wade
- Mail: [email protected]
- https://hansonwade.com/
Speaker
- See the full list of speakers here
Health and Safety
- All attendees will be required to complete a health declaration prior to attending the event. As part of this, attendees must declare that they are either fully vaccinated and /or have completed a negative Lateral Flow Test or PCR Test within 48 hours of the event*.
- For further information around Health and Safety onsite, please visit the FAQ page here.
- *Please note, this is subject to change at any time without prior notice.
Listed under MitoGlobal Events.
Labels:
2022, MitoGlobal
